Literature DB >> 29611388

Phenotypic and Genomic Characterization of AmpC-Producing Klebsiella pneumoniae From Korea.

Mattia Palmieri1, Stephane Schicklin2, Andreu Coello Pelegrin1, Sonia Chatellier1, Christine Franceschi3, Caroline Mirande3, Yeon Joon Park4, Alex van Belkum5.   

Abstract

The prevalence of multidrug-resistant gram-negative bacteria has continuously increased over the past few years; bacterial strains producing AmpC β-lactamases and/or extended-spectrum β-lactamases (ESBLs) are of particular concern. We combined high-resolution whole genome sequencing and phenotypic data to elucidate the mechanisms of resistance to cephamycin and β-lactamase in Korean Klebsiella pneumoniae strains, in which no AmpC-encoding genes were detected by PCR. We identified several genes that alone or in combination can potentially explain the resistance phenotype. We showed that different mechanisms could explain the resistance phenotype, emphasizing the limitations of the PCR and the importance of distinguishing closely-related gene variants. © The Korean Society for Laboratory Medicine.

Entities:  

Keywords:  AmpC; Antibiotic resistance; Klebsiella pneumoniae; Korea; Whole Genome Sequencing

Mesh:

Substances:

Year:  2018        PMID: 29611388      PMCID: PMC5895867          DOI: 10.3343/alm.2018.38.4.367

Source DB:  PubMed          Journal:  Ann Lab Med        ISSN: 2234-3806            Impact factor:   3.464


The AmpC β-lactamases produced by Enterobacteriaceae are clinically relevant enzymes that can hydrolyze penicillins, cephamycins such as cefoxitin, as well as broad-spectrum cephalosporins such as ceftazidime or cefotaxime. Moreover, penicillinase inhibitors are ineffective against these enzymes. The cephalosporinases encoded in the chromosome of group 3 Enterobacteriaceae were originally present only in Enterobacter spp., Morganella spp., Citrobacter spp., and a number of other species. Following the acquisition of ampC genes via transmissible plasmids, cephalosporinases began to appear in Escherichia coli and Klebsiella pneumoniae as well [1]. Distinguishing between acquired ampC and chromosomal ampC is possible by gene amplification only. Plasmid-mediated AmpC enzyme production is less common than production of extended-spectrum β-lactamases, and its detection remains difficult in the presence of other enzymes, leading to an underestimation of this resistance mechanism [2]. We identified K. pneumoniae strains that exhibited an AmpC phenotype in the absence of PCR-detectable ampC genes. Furthermore, we used genome sequencing and identified other β-lactamase genes that could possibly explain the resistance phenotype of these strains. A total of 257 K. pneumoniae strains were collected from 17 hospitals in Korea. No ethical clearance was required for this study since patient data were not included and the source of the strains was anonymous. The strains were collected in 2014 and were stored at −80℃ until use. Before use, the strains were subcultured on MacConkey agar and were deposited in the central laboratory (Seoul St. Mary's Hospital). Of the total isolates, 39 were intermediately resistant or resistant to cefoxitin, and 31 of these expressed a plasmid-mediated DHA-type AmpC β-lactamase; this enzyme confers resistance to cephamycins and oxyimino-cephalosporins and is most likely characterized by inducible production. Phenotypic detection of AmpC was performed using a modified disk-based method, with boronic acid as an AmpC inhibitor [3]. Briefly, the isolates were tested using a standard cefoxitin disk (30 µg) and a cefoxitin disk supplemented with 400 µg of phenylboronic acid (Sigma-Aldrich, Saint-Quentin Fallavier, France). Isolates were considered AmpC-positive if the zone of inhibition surrounding the phenylboronic acid-cefoxitin disk was ≥5 mm larger than that surrounding the cefoxitin disk. The isolates were also tested using a multiplex PCR assay that identifies plasmid-mediated ampC genes [4]. Five ampC-PCR-negative strains exhibiting the AmpC phenotype were subjected to further phenotypic characterization and whole genome sequencing (WGS) for detailed analyses of resistance gene content. The antimicrobial susceptibilities of the strains were tested using the VITEK2 instrument (bioMérieux, Marcy-l'Étoile, France). DNA was extracted using the Mo Bio kit (QIAGEN, Hilden, Germany) and sequenced using the Illumina MiSeq system with a 2×150 bp approach and a minimum coverage of 100×. The reads were assembled using A5-miseq, and the scaffolding was performed using SSPACE. The ResFinder online tool (https://cge.cbs.dtu.dk/services/ResFinder/) was used to assess the presence of (acquired) antimicrobial resistance genes, while the BioNumerics 7 software (Applied Maths, Sint-Martens-Latem, Belgium) was used to define microbial multi locus sequence types (MLST). The same tool was used to assess mutations in the ompK35 and ompK36 genes, which encode porins important for antibiotic uptake; mutation of these genes can lead to impermeability to several types of β-lactam drugs [5]. The five ampC-PCR-negative K. pneumoniae strains (all originating from urine samples and collected in different cities in Korea) belonged to four different sequence types (ST) (Table 1). Phenotypic characterization showed that all strains, except for 1606284, were resistant to cefoxitin; all strains were resistant to ampicillin/sulbactam and ticarcillin/clavulanic acid; and all but two strains (1606283 and 1606285) were resistant to piperacillin/tazobactam, according to the EUCAST breakpoints (Table 2). As the ResFinder results confirmed the absence of AmpC-encoding genes, we investigated which other genes could produce an AmpC-like phenotype.
Table 1

Multilocus sequence type (MLST) and metadata of the five Klebsiella pneumoniae strains subjected to whole genome sequencing

StrainMLSTCountryCitySpecimen sourceDisease
1606283ST17KoreaPusanUrineUrinary tract infection [chronic kidney disease]
1606284ST11KoreaPusanUrineUrinary tract infection [acute tubulo-interstitial nephritis]
1606285ST584KoreaSeoulUrineAbscess [benign neoplasm of central nervous system]
1606286ST307KoreaIncheonUrineOther [cerebral infarction due to embolism of cerebral arteries]
1606287ST307KoreaSeoulUrineOther [upper gastrointestinal bleeding]
Table 2

Minimum inhibitory concentrations in micrograms per millilitre of the five Klebsiealla pneumoniae strains

StrainAmpicillinAmpicillin/SulbactamTicarcillinTicarcillin/ClavulanatePiperacillinPiperacillin/TazobactamCefoxitinCefotaximeCeftazidime
1606283≥ 32≥ 32≥ 128= 64≥ 128= 16= 32= 16≤1
1606284≥ 32≥ 32≥ 128≥ 128≥ 128≥ 128≥ 64= 8≥ 64
1606285≥ 32= 16≥ 128= 64≥ 128= 8≤ 4= 2≥ 64
1606286≥ 32≥ 32≥ 128≥ 128≥ 128≥ 128≥ 64≥ 64≥ 64
1606287≥ 32≥ 32≥ 128≥ 128≥ 128≥ 128≥ 64≥ 64≥ 64
The enzymatic mechanisms conferring resistance or decreased susceptibility to β-lactamase inhibitors and cephamycins in K. pneumoniae include plasmid-mediated AmpC-type β-lactamase (p-AmpC) [1]; hyper-production of plasmid-mediated class A β-lactamases, such as TEM-1 and SHV-1 [67]; production of inhibitor-resistant TEM (IRT) β-lactamases [89]; plasmid-mediated OXA-type β-lactamase, such as OXA-1 [10]; and complex mutant TEMs (CMT), which are enzymes that combine IRT- and extended-spectrum β-lactamase (ESBL)-type substitutions [11]. ResFinder analyses identified at least one gene in each strain that could fully or partially explain the presence of a resistance phenotype in an ampC-PCR-negative background (Table 3).
Table 3

The bla genes conferring resistance to β-lactams identified by ResFinder and BioNumerics analysis

StraintemShvctx-moxalenompK
1606283shv-11(2b)ctx-m-14
1606284tem-1b(2b)shv-11(2b)oxa-1(2d)ompk35truncated
1606285tem-1b(2b)len-12
1606286shv-28ctx-m-15(2be)oxa-1(2d)
1606287tem-102(2be)shv-28ctx-m-15(2be)oxa-1(2d)

The Bush functional classification, when available, is indicated within parenthesis.

ResFinder showed the presence of the blaOXA-1 gene in three of five strains (1606284, 1606286, and 1606287); two of these strains also contained blaCTX-M-15 and blaSHV-28, and the third strain also possessed blaTEM-1b and blaSHV-11. These three strains were associated with high minimum inhibitory concentrations (MICs) for both penicillin plus β-lactamase inhibitor combinations tested and for cefoxitin. Strain 1606283 carried blaCTX-M-14, encoding an ESBL able to confer decreased susceptibility to β-lactamase inhibitors; this strain demonstrated resistance to sulbactam and clavulanate and intermediate resistance to tazobactam. These results and the high cefoxitin MICs suggested impermeability to cephamycins. BioNumerics analysis of the ompK genes did not reveal any genetic mutations leading to frameshifts resulting in a truncated protein. However, we cannot exclude the presence of mutations leading to altered functionality or limited gene expression. Strain 1606285 carried blaTEM-1B together with blaLEN-12; overexpression of blaTEM-1B can decrease the susceptibility to combined treatment with penicillins and β-lactamase inhibitors. Overexpression of blaTEM-1 has been associated with promoters p3, pa/pb, p4, and p5 [12]; we observed that both strains carrying the tem-1b gene harbored the p3 promoter upstream of the β-lactamase gene. Finally, analysis of the ompK genes revealed that only the ompK35 in strain 1606284 contained a deletion that resulted in a frameshift and, consequently, a truncated protein. In this pilot study, we show that discrepancies between resistance phenotypes and PCR results can be elucidated and possibly corrected using genomic data. Although these results are not unexpected, our analyses demonstrate that genomics data could be a valuable addition to PCR-based targeted gene testing. We have not included functional studies to prove that the new genes identified are causal of the phenotype because this was beyond the scope of the study. Furthermore, we assume that previously reported associations between phenotypes and the presence of certain genes (such as blaCTX-m-14, blaTEM-1b, and blaOXA-1) are correct and reliable [13]. Although PCR analysis is preferable in many settings because of the high cost and complexity of genomic analysis, we recommend that national reference laboratories adopt the pipeline proposed in our current analysis.
  13 in total

1.  Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

Authors:  F Javier Pérez-Pérez; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Promoters P3, Pa/Pb, P4, and P5 upstream from bla(TEM) genes and their relationship to beta-lactam resistance.

Authors:  Marie Frédérique Lartigue; Véronique Leflon-Guibout; Laurent Poirel; Patrice Nordmann; Marie-Hélène Nicolas-Chanoine
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

3.  Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.

Authors:  Frédéric Robin; Julien Delmas; Cédric Schweitzer; Olivier Tournilhac; Olivier Lesens; Catherine Chanal; Richard Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

4.  Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence.

Authors:  Yu-Kuo Tsai; Chang-Phone Fung; Jung-Chung Lin; Jiun-Han Chen; Feng-Yee Chang; Te-Li Chen; L Kristopher Siu
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction.

Authors:  E Miró; M del Cuerpo; F Navarro; M Sabaté; B Mirelis; G Prats
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790

6.  Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis.

Authors:  Philip E Coudron
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

7.  Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended- spectrum-beta-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction.

Authors:  Rebecca I Waltner-Toews; David L Paterson; Zubair A Qureshi; Hanna E Sidjabat; Jennifer M Adams-Haduch; Kathleen A Shutt; Mark Jones; Guo-Bao Tian; Anthony W Pasculle; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

8.  Characterization of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from the community in Morocco.

Authors:  Abouddihaj Barguigua; Fatima El Otmani; Mustapha Talmi; Fatna Bourjilat; Fatima Haouzane; Khalid Zerouali; Mohammed Timinouni
Journal:  J Med Microbiol       Date:  2011-05-05       Impact factor: 2.472

Review 9.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

10.  Detection of AmpC β Lactamases in Gram-negative Bacteria.

Authors:  Gunjan Gupta; Vibhor Tak; Purva Mathur
Journal:  J Lab Physicians       Date:  2014-01
View more
  3 in total

1.  Role of phenotypic testing in determining the mechanism of resistance in Gram-negative bacilli & risk factors for meropenem resistance.

Authors:  Kavita Raja; Molly Antony; Reeja Rani; Gracyamma Bridget
Journal:  Indian J Med Res       Date:  2019-02       Impact factor: 2.375

2.  High clinical impact of rapid susceptibility testing on CHROMID ESBL® medium directly from swabs.

Authors:  Álvaro Romo-Ibáñez; Elisabeth Calatrava-Hernández; Blanca Gutiérrez-Soto; Mercedes Pérez-Ruiz; José María Navarro-Marí; José Gutiérrez-Fernández
Journal:  Ann Transl Med       Date:  2020-05

3.  Clinical Features and Risk Factors Associated With 30-Day Mortality in Patients With Pneumonia Caused by Hypervirulent Klebsiella pneumoniae (hvKP).

Authors:  Jeong-Hwan Hwang; Mallikarjun Handigund; Joo-Hee Hwang; Yong Gon Cho; Dal Sik Kim; Jaehyeon Lee
Journal:  Ann Lab Med       Date:  2020-06-17       Impact factor: 3.464

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.